Chemed Corporation (CHE)
| Market Cap | 7.14B +12.1% |
| Revenue (ttm) | 2.66B +5.2% |
| Net Income | 282.40M +1.3% |
| EPS | 20.93 +10.5% |
| Shares Out | 13.02M |
| PE Ratio | 26.20 |
| Forward PE | 20.18 |
| Dividend | $2.80 (0.51%) |
| Ex-Dividend Date | Aug 17, 2026 |
| Volume | 12,119 |
| Open | n/a |
| Previous Close | 541.92 |
| Day's Range | n/a |
| 52-Week Range | 365.21 - 562.24 |
| Beta | 0.51 |
| Analysts | Buy |
| Price Target | 617.00 (+12.52%) |
| Earnings Date | Oct 27, 2026 |
About CHE
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, doctors, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates through two segments: VITAS and Roto-Rooter segments. The company offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company also provides dire... [Read more]
Financial Performance
In 2025, Chemed's revenue was $2.53 billion, an increase of 4.06% compared to the previous year's $2.43 billion. Earnings were $265.24 million, a decrease of -12.17%.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for CHE stock is "Buy." The 12-month stock price target is $617.0, which is an increase of 12.52% from the latest price.
News
Chemed price target raised to $585 from $548 at RBC Capital
RBC Capital raised the firm’s price target on Chemed (CHE) to $585 from $548 and keeps a Sector Perform rating on the shares. The company posted another strong result in…
Chemed price target raised to $675 from $650 at UBS
UBS raised the firm’s price target on Chemed (CHE) to $675 from $650 and keeps a Buy rating on the shares.
Chemed price target raised to $625 from $590 at Oppenheimer
Oppenheimer raised the firm’s price target on Chemed (CHE) to $625 from $590 and keeps an Outperform rating on the shares following quarterly results, with Vitas strength outweighing Roto-Rooter margi...
Chemed Earnings Call Transcript: Q3 2026
Q3 revenue rose 10.6% and adjusted diluted EPS increased 28.1%, led by VITAS growth. Roto-Rooter revenue advanced, but marketing and fuel costs pressured margins; FY2026 adjusted EPS is expected at or above the high end of guidance.
Chemed Earnings release: Q3 2026
Chemed released its Q3 2026 earnings on October 28, 2026, summarizing the period's financial results.
Chemed Quarterly report: Q3 2026
Chemed has published its Q3 2026 quarterly earnings report on October 28, 2026.
Chemed price target raised to $555 from $550 at BofA
BofA raised the firm’s price target on Chemed (CHE) to $555 from $550 and keeps a Neutral rating on the shares. Q3 EBITDA beat by 2% and EPS beat by…
Chemed upgraded to Buy from Hold at Jefferies
Jefferies upgraded Chemed (CHE) to Buy from Hold with a price target of $620, up from $520. The firm expects the shares to “gradually re-rate” toward 15-times EBITDA as the…
Chemed reports Q3 adjusted EPS $6.75, consensus $6.44
Reports Q3 revenue $690.94M, consensus $685.04M. The company said, “As of September 30, 2026, Chemed (CHE) had total cash and cash equivalents of $48.4 million and $236.0 million in long-term…
Chemed backs FY26 adjusted EPS view $25.00-$25.75, consensus $25.49
The company said, “Based on the Company’s financial results through September 30, 2026, we estimate that we will be at or slightly above the high-end of our full-year 2026 adjusted…
Chemed Reports Third-Quarter 2026 Results
CINCINNATI, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), the nation's largest providers of end-of-life care, and Roto...
Big tech is wobbling. Goldman Sachs says it's time to buy these 23 unloved stocks instead.
Goldman Sachs says consumer-facing laggard stocks are the best way forward as earnings growth is set to slow next year and big tech stocks struggle.
Chemed To Report Third Quarter 2026 Earnings October 27, Related Conference Call To Be Held On October 28
CINCINNATI, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the third quarter ended September 30, 2026, on Tuesday, October ...
Chemed initiated with a Buy at UBS
UBS initiated coverage of Chemed (CHE) with a Buy rating and $650 price target The firm believes the company can achieve low-double-digit adjusted earnings growth going forward. Based on the…
Roto-Rooter Buys Largest Franchisee Territory
CINCINNATI, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Roto-Rooter Services Company, a wholly owned subsidiary of Chemed Corporation ("Chemed") (NYSE: CHE) announced it has acquired the largest independent Ro...
Chemed Transcript: 2026 Jefferies Healthcare Services and Technology Conference
Second quarter results exceeded expectations, prompting raised guidance. VITAS continues to outperform, driven by operational improvements and Florida expansion, while Roto-Rooter has stabilized despite higher marketing costs. Demographic trends support strong hospice demand and workforce investments remain a priority.
Chemed Corporation to Present at the Jefferies 2026 Healthcare Services Conference
CINCINNATI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE: CHE) today announced that it will deliver a presentation at the Jefferies 2026 Healthcare Services and Technology Conference on...
Chemed unit claimed to misdiagnose dementia patients, Capitol Forum says
The Capitol Forum stated in a post to X: “Chemed (CHE): Vitas Healthcare Misdiagnosed Dementia Patients and ‘Fudged’ Evaluation Scores in Order to Admit Them into Hospice; Expert Who Reviewed…
Chemed boosts quarterly dividend to 70c from 60c per share
Chemed (CHE) Corporation announced that the board of directors has declared a quarterly cash dividend of 70c per share on the company’s capital stock, payable on September 3 to shareholders…
Chemed Corporation Declares Quarterly Dividend of 70 Cents
CINCINNATI, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 70-cents per share on the Company's ca...
Chemed price target raised to $590 from $500 at Oppenheimer
Oppenheimer raised the firm’s price target on Chemed (CHE) to $590 from $500 and keeps an Outperform rating on the shares following quarterly results. Overall, Vitas continues to shoulder the…
Chemed price target raised to $548 from $436 at RBC Capital
RBC Capital analyst Ben Hendrix raised the firm’s price target on Chemed (CHE) to $548 from $436 and keeps a Sector Perform rating on the shares. The company delivered another…
Chemed Earnings Call Transcript: Q2 2026
VITAS delivered strong Q2 2026 results, driving higher revenue and margins, while Roto-Rooter maintained stable performance despite increased marketing costs. Full-year guidance was raised for VITAS, with robust cash flow supporting acquisitions and share repurchases.
Chemed Earnings release: Q2 2026
Chemed released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
Chemed Slides: Q2 2026
Chemed has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 29, 2026.